Drugs clean-up could cost £26bn

November 2011
Utility Week;11/18/2011, p4
Trade Publication
The article informs that the European Commission could levy England up to 26 billion pounds over 20 years to remove hormones and pharmaceutical drugs from water sources despite scant evidence of harm.


Related Articles

  • Fish drug snagged in politics. MacKenzie, Debora // New Scientist;2/24/96, Vol. 149 Issue 2018, p7 

    Reports on the European Commission's (EC) banning of somatosalm, a generic drug that can reduce the death rate of farmed salmon. European Union's (EU) banning of BST, the growth hormone given to cows to increase their milk production; Mode of action of somatosalm; Reason why an EU committee...

  • EU blocks DTC-like experiment. Dickinson, James G. // Medical Marketing & Media;Dec2002, Vol. 37 Issue 12, p30 

    Focuses on the vote of European Parliament to stop the proposal of European Commission to allow patients suffering from AIDS, asthma and diabetes to get treatment information from drug manufacturers. Concerns over drug communications; Restriction of non-solicited advertising.

  • EU guidelines regulate medical packs.  // Packaging Magazine;10/24/2002, Vol. 5 Issue 19, p24 

    Reports on the guidelines released by the European Commission on packaging of medical product, labelling and inserted leaflets containing additional information. Duration of treatment; Language used; Dimension of packaging.

  • EU TO PILOT SOME DTC ADVERTISING.  // Medical Marketing & Media;Oct2001, Vol. 36 Issue 10, p38 

    Reports the plans of the European Commission to conduct a pilot test of prescription drugs for asthma, diabetes and AIDS.

  • Europe plans molecular screening center for translational research. Laursen, Lucas // Nature Medicine;Apr2012, Vol. 18 Issue 4, p477 

    The article reports that the Innovative Medicines Initiative (IMI), in partnership with the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA, have invited proposals to create a molecular screening facility for drug discovery in Europe.

  • European Commission to speed up access to drugs.  // PharmacoEconomics & Outcomes News;3/17/2012, Issue 649, p11 

    The article reports on a proposal from the European Commission to reduce the time taken of national decisions on pricing and reimbursement for drugs to enter the market.

  • Sandoz Gains European Approval for First Generic Biologic. Scott, Alex // Chemical Week;5/3/2006, Vol. 168 Issue 15, p22 

    The article reports on the authorization given by the European Commission for the use of Omnitrope, Sandoz's generic biologic human growth hormone, across the European Union. The authorization is the first approval in Europe of a generic biologic, otherwise known as biogeneric or biosimilar, and...

  • Merck Serono's Pergoveris Approved in EU.  // BioPharm International;Aug2007, Vol. 20 Issue 8, p12 

    The article announces that the European Commission has granted a marketing authorization for Merck Serono SA's Pergoveris. It is the first biotechnology product intended for the stimulation of follicular development in women with severe luteinizing hormone (LH) and follicle stimulating hormone...

  • EC minsters take hard look at prices of drugs. Taylor, Robert // BMJ: British Medical Journal (International Edition);6/5/93, Vol. 306 Issue 6891, p1501 

    Focuses on the investigation of the European Commission on the prices of drugs in Europe. Impact of high prices of medicine on pensioners; Reason for refusal of drug companies to sell to some countries; Role of British government in reducing the tobacco consumption; Proposal to raise excise...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics